Alto Neuroscience (NYSE:ANRO) Issues Earnings Results

Alto Neuroscience (NYSE:ANRO) posted its quarterly earnings data on Wednesday. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08, FiscalAI reports.

Alto Neuroscience Price Performance

ANRO traded up $0.34 on Wednesday, reaching $29.12. 278,063 shares of the company’s stock were exchanged, compared to its average volume of 365,606. The stock has a market cap of $1.02 billion, a PE ratio of -12.03 and a beta of 1.06. Alto Neuroscience has a twelve month low of $3.02 and a twelve month high of $29.70. The stock’s fifty day moving average price is $25.24 and its 200-day moving average price is $22.48. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP grew its holdings in shares of Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after purchasing an additional 1,535,000 shares during the period. Vivo Capital LLC purchased a new position in Alto Neuroscience during the fourth quarter worth about $18,433,000. Ikarian Capital LLC boosted its holdings in Alto Neuroscience by 368.2% in the 4th quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 405,000 shares during the last quarter. Millennium Management LLC boosted its holdings in Alto Neuroscience by 99.5% in the 4th quarter. Millennium Management LLC now owns 629,985 shares of the company’s stock valued at $11,214,000 after purchasing an additional 314,227 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Alto Neuroscience in the 2nd quarter valued at approximately $240,000.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Wall Street Zen downgraded shares of Alto Neuroscience from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Wedbush boosted their price objective on Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Finally, Robert W. Baird decreased their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and an average target price of $35.25.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.